You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

BENZGALANTAMINE GLUCONATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for benzgalantamine gluconate and what is the scope of freedom to operate?

Benzgalantamine gluconate is the generic ingredient in one branded drug marketed by Alpha Cognition and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Benzgalantamine gluconate has twenty-four patent family members in seventeen countries.

One supplier is listed for this compound.

Summary for BENZGALANTAMINE GLUCONATE
International Patents:24
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:BENZGALANTAMINE GLUCONATE at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for BENZGALANTAMINE GLUCONATE
Generic Entry Date for BENZGALANTAMINE GLUCONATE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, DELAYED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for BENZGALANTAMINE GLUCONATE

US Patents and Regulatory Information for BENZGALANTAMINE GLUCONATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alpha Cognition ZUNVEYL benzgalantamine gluconate TABLET, DELAYED RELEASE;ORAL 218549-002 Jul 26, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Alpha Cognition ZUNVEYL benzgalantamine gluconate TABLET, DELAYED RELEASE;ORAL 218549-003 Jul 26, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Alpha Cognition ZUNVEYL benzgalantamine gluconate TABLET, DELAYED RELEASE;ORAL 218549-001 Jul 26, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Alpha Cognition ZUNVEYL benzgalantamine gluconate TABLET, DELAYED RELEASE;ORAL 218549-002 Jul 26, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Alpha Cognition ZUNVEYL benzgalantamine gluconate TABLET, DELAYED RELEASE;ORAL 218549-001 Jul 26, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Alpha Cognition ZUNVEYL benzgalantamine gluconate TABLET, DELAYED RELEASE;ORAL 218549-003 Jul 26, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for BENZGALANTAMINE GLUCONATE

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2022150917 ⤷  Sign Up
Denmark 1940817 ⤷  Sign Up
European Patent Office 1777222 Inhibiteurs de la cholinesterase avec une perméabilité améliorée de la barrière ématoencéphalique pour le traitement de troubles cognitifs (Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment) ⤷  Sign Up
China 116761612 α-1062葡糖酸盐的固体形式 (Solid forms of alpha-1062 gluconate) ⤷  Sign Up
Germany 602006015338 ⤷  Sign Up
Canada 2623114 AMPLIFICATEURS CHOLINERGIQUES DE PERMEABILITE DE LA BARRIERE SANG-CERVEAU AMELIOREE POUR LE TRAITEMENT DE MALADIES ACCOMPAGNEES D'UNE DEFICIENCE COGNITIVE (CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT) ⤷  Sign Up
South Korea 20230131220 알파-1062 글루코네이트의 고체 형태 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.